The Translational Impact Research (TIR) funding program supports large-scale translational research projects in RNA-based therapeutics, which address D2R鈥檚 strategic priorities, and have a measurable translational impact on the health of Canadians.

In the first funding cycle launched in 2024, 11 Letters of Intent were received of which four were invited to submit full applications. Three full applications were received and awarded. View a summary of the review and selection process.

Funded project听summaries

听

RNA therapy for a severe and ultra-rare disease

Schinzel-Giedion Syndrome is a devastating and rare genetic disease leading to neurological deterioration and Cystic Fibrosis-like lung disease. Most people with SGS die in the first decade of life and there is no treatment that targets the underlying cause of disease. SGS is caused by missense mutations in the SETBP1 gene which result in an accumulation of the SETBP1 protein. By reducing the level of SETBP1 mRNA, SETBP1 protein levels can be decreased offering a potential treatment for SGS. Using antisense oligonucleotides (ASO), we have successfully reduced SETBP1 protein levels in SGS patient derived progenitor brain cells and SGS mouse disease models. The purpose of this grant is to manufacture and test an RNA therapy for SGS and use it to reduce seizure burden in one SGS individual. We will use a unique clinical trial mechanism in Canada, the Single Patient Clinical Trial. We hope to reduce suffering in the daily life of children suffering from SGS.

Principal investigator: Carl Ernst (91导航视频)

Co-investigators : Larry Lands (MUHC), Darcy Wagner (MUHC), Keith Murai (MGH), Ken Myers (MCH), Ziv Gan-Or (MNI), Sebastian Jacquemont (St Justine), Raluca Pana (MNI), Alexander Weil (St Justine), Karl Muchantef (MCH)

Award duration: 3 years

Relevant D2R axes: RNA Therapeutics (Axis 2) Clinical Research, Acceleration, and Implementation (Axis 4) , Population Studies and Genomic Medicine (Axis 1)

听

Innovative RNA therapies offer new hope for patients affected by POLR3-related leukodystrophy

Leukodystrophies are rare genetic brain disorders affecting previously healthy children. POLR3-related hypomyelinating leukodystrophy (POLR3-HLD) is characterized by reduced white matter (myelin) production in the brain. It results from mutations in genes that code for RNA polymerase III (Pol III), an essential complex for producing RNA, including transfer RNAs (tRNAs) necessary for protein production. This project aims to develop RNA-based treatments for POLR3-HLD through three strategies: first, using antisense oligonucleotides (ASOs) to target and modify the disease-causing genetic message in affected patients; second, restoring POLR3A function (a critical Pol III subunit) by delivering healthy mRNA via lipid nanoparticles (LNPs); and finally, we are exploring an ASO approach to reduce MAF1, a Pol III inhibitor, to enhance its activity. These therapies will be preclinically tested in cell and mouse models to ensure safety and efficacy, with patient, organization, and industry support to ensure rapid transition to clinical trial.

Principal investigator: Genevi猫ve Bernard (Research Institute of the 91导航视频 Health Centre)

Co-investigators: Thomas Durcan (91导航视频), Timothy Kennedy (91导航视频), 91导航视频), Philippe Huot (91导航视频)

Collaborators: Guillaume Bourque (91导航视频), Masad Damha (91导航视频), Pieter Cullis (University of British Columbia), Ian Willis, (Albert Einstein College of Medicine), Austen Milnerwood (91导航视频), Nahum Sonenberg (91导航视频), Fran莽ois-Xavier Lacasse (Universit茅 de Montr茅al)

Partnering organizations : Jude Tallman and Family, Fondation Les Amis d'Elliot, Leuco Action, Yaya Foundation for 4H Leukodystrophy, Montreal Children's Hospital Foundation, RI-MUHC, Early Drug Discovery Unit (91导航视频), NanoCore, C3G Platform, Andor Technology, Dendrotek Biosciences, Parse Biosciences, RNA technologies & Therapeutics Inc.

Award duration: 3 years

Relevant D2R axes: RNA Therapeutics (Axis 2) Clinical Research, Acceleration, and Implementation (Axis 4) , Data Science, Bioinformatics, and Computing in Personalized Medicine (Axis 5)

听

The Jerry Pelletier initiative: Diagnostic and therapeutic innovations for rare cancers

Despite great advances overall in cancer therapy, patients with rare subtypes of tumours do not benefit adequately from personalised treatments due to the lack of basic knowledge of the underlying biological factors that drive these cancers. Since these patients often do not respond to standard-of-care approaches and then become resistant to therapies currently available, physicians at present have limited treatment options. We are undertaking a coordinated multi-disciplinary program that will use advanced genomics to identify the most viable biomarkers and likely therapeutic targets for patients with rare types of tumours and then exploit this knowledge to obtain RNA-based and other treatments adapted to each patient. Furthermore, our comprehensive genomic studies and tumour modeling of rare cancer subtypes will generate resources that can be used by the research community to identify new ways to tackle these difficult-to-treat malignancies.

Principal investigator: Mark Lathrop (91导航视频), Morag Park (91导航视频)

Co-investigators: Gerald Batist (91导航视频), Guillaume Bourque (91导航视频), Thomas Duchaine, (91导航视频), William Foulkes (91导航视频), Livia Garzia (91导航视频), Sidong Huang (91导航视频), Nada Jabado (91导航视频), Mark Lathrop (91导航视频), Morag Park (91导航视频), Ioannis Ragoussis (91导航视频), Yasser Riazalhosseini (91导航视频), Ramy Saleh (91导航视频)

Collaborators: Mark Basik (91导航视频), Mathieu Blanchette (91导航视频), Julia Burnier (91导航视频), Guojun Chen (91导航视频), David Juncker (91导航视频), Wassim Kassouf (91导航视频), Claudia Kleinman (91导航视频), Sampath Loganathan (91导航视频), Raquel Cuella Martin (91导航视频), Heather Melichar (91导航视频), William Muller (91导航视频), Peter Siegel (91导航视频), Hanadi Sleiman (91导航视频), Nahum Sonnenberg (91导航视频), Simon Tanguay (91导航视频), Ian Watson (91导航视频)

Post-doctoral fellows: Rocio Conforti Ayelem (91导航视频), Zohreh Mehrjoo (91导航视频), Monica Lara Marquez (91导航视频), Behrang Sharif (91导航视频)

Partnering organizations: Oxford Nanopore Technologies, 10x Genomics

Award duration: 3 years

Relevant D2R axes: Population Studies and Genomic Medicine (Axis 1) RNA Therapeutics (Axis 2) , Clinical Research, Acceleration, and Implementation (Axis 4)

听